Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy

• Status: Unknown status
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Severe peanut allergy is different from other allergic reactions because it can lead to fatal reactions and is an invisible disability. There is no cure today. The purpose of this study is to treat children and adolescents with severe peanut allergy with oral immunotherapy with peanuts under the protection of anti-IgE (immunoglobulin E) antibodies (omalizumab), and thereby inducing tolerance to peanuts. The treatment will be monitored by basophil cell stimulation (CD-sens).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Caroline Nilsson
• Treatments: Omalizumab

Criteria

Inclusion Criteria:

• IgE to peanut, Ara h 1, Ara h 2 and Ara h 3

• IgE to an airborne allergen i.e. cat, dog, horse, birch, grass etc.

• Clinical allergic reactions to peanut the last 5 years

• Positive conjunctival challenge to the selected airborne allergen

• Positive CD-sens to peanut and the selected airborne allergen

• IgE according to the recommendations of the manufacturer

• Written consent

Exclusion Criteria:

• No severe diseases like renal failure, hart disease, immunodeficiency, diabetes or other severe chronic diseases

• Pregnancy

• No previous hypersensitivity reactions to sucrose, histidine, polysorbat 20 or omalizumab